Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen Revenue Decline Continues in Q3 as Net Loss Widens 32 Percent

NEW YORK, Nov. 3 (GenomeWeb News) - Nanogen has reported third-quarter revenue of $1.1 million, down from $1.7 million in the comparable period a year ago.


The results match the revenue and related decline that the firm posted in the second quarter of 2004. Product revenue for the three months ended Sept. 30 fell to $671,000 from $752,000 for the third quarter of 2003.


Nanogen's net loss grew to $9.4 million, or $.28 per share, from $7.1 million, or $.33 per share, for the third quarter last year. The results include the first full quarter of activity related to its SynX subsidiary, which the firm acquired in April.


The San Diego-based microarray and diagnostics firm reported a slight increase in research and development spending to $4.5 million from $4.3 million in the third quarter of 2003. It finished the quarter with $53.1 million in cash, cash equivalents, and short-term investments.


Nanogen is in the process of acquiring Epoch Biosciences in an all-stock transaction valued at roughly $60 million. Shareholders of both firms are scheduled to vote on the merger on Dec. 8, and the merger partners expect to complete the deal by the end of the year.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.